Decreased nociceptin receptors are related to resilience and recovery in college women who have experienced sexual violence: therapeutic implications for PTSD

Rajesh Narendran, M.D.[1,2], **Savannah Tollefson, B.S.**[1], **Kelli Fasenmyer, B.S.**[1], **Jennifer Paris, MEd, MSL.**[2], **Michael L. Himes, B.S.**[1], **Brian Lopresti, MSNE.**[1], **Roberto Ciccocioppo, Ph.D.**[3], **N. Scott Mason, Ph.D.**[1]

[1]Department of Radiology, University of Pittsburgh, Pittsburgh, PA

[2]Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA

[3]School of Pharmacy, Pharmacology Unit, University of Camerino, Camerino, Italy

Abstract

OBJECTIVE: Post-traumatic stress disorder (PTSD) is a stress disorder that develops in only some individuals following a traumatic event. Data suggest that a substantial fraction of women recover after sexual violence. Thus, the investigation of stress and anti-stress neuropeptides in this sample has the potential to inform the neurochemistry of resilience following trauma. Nociceptin is an anti-stress neuropeptide in the brain that promotes resilience in animal models of PTSD.

METHODS: $[^{11}C]NOP$-1A PET was used to measure the in vivo binding to nociceptin receptors in 18 college women who had experienced sexual violence irrespective of whether they met DSM-5 diagnostic criteria for PTSD. $[^{11}C]NOP$-1A data from 18 healthy controls was also included to provide a contrast with the sexual violence group. $[^{11}C]NOP$-1A total distribution volume (V_T) in the regions of interest were measured with kinetic analysis using the arterial input function. The relationships between regional V_T and Clinician-Administered PTSD Scale total symptom and subscale severity were examined using correlational analyses.

RESULTS: No differences in $[^{11}C]NOP$-1A V_T were noted between the sexual violence and control groups. V_T in the midbrain and cerebellum were positively correlated with PTSD total symptom severity in the *past month* prior to PET. Intrusion/re-experiencing and avoidance subscale symptoms drove this relationship. Stratification of subjects by a DSM-5 PTSD diagnosis and contrasting their V_T with that in controls showed no group differences.

CONCLUSION: Decreased midbrain and cerebellum nociceptin receptors are associated with less severe PTSD symptoms. Medications that target nociceptin should be explored to prevent and treat PTSD.

Correspondence: R. Narendran, M.D., University of Pittsburgh PET Facility, UPMC Presbyterian, B-938, Pittsburgh, PA 15213, Telephone: (917)-270-4551, Fax: (412)-647-0700, narendranr@upmc.edu.

INTRODUCTION

Post-traumatic stress disorder (PTSD) is a stress disorder characterized by altered fear conditioning and memory reconsolidation following a traumatic event (1). The traumatic event most commonly preceding PTSD in women is sexual violence. A substantial fraction of women will experience sexual violence in adolescence or adulthood. An estimated 30 to 80% of these women will be diagnosed with PTSD during their lifetime, and current PTSD prevalence in this group approaches 15% (2–5). In contrast, the lifetime and current prevalence rates for PTSD (both genders) from all trauma is 6.8% and 3.6%, respectively (6). These trends suggest both higher prevalence of and greater recovery from PTSD following sexual violence as compared with other traumas. Understanding the neurochemistry of recovery in women who have experienced sexual violence has the potential to inform therapeutic strategies to prevent and treat the symptoms of PTSD.

Ross and colleagues outline a framework for PTSD in which the three core DSM-5 symptom clusters of intrusive recollection, avoidance, and increased arousal can be viewed as abnormalities in classical fear conditioning, negative reinforcement, and sympathetic nervous system/hypothalamic-pituitary-adrenal axis stress response, respectively (1). This allows for the conceptualization of PTSD primarily as a learning and memory disorder in which abnormal trauma memory reconsolidation/extinction leads to intrusive thoughts and subsequent avoidance of trauma-related memories (i.e., DSM-5 PTSD criterion B and C symptoms). Other PTSD symptoms including negative alterations in mood and cognition and increased arousal/reactivity (i.e., criterion D and E symptoms) are secondary manifestations. FDA approved medications to treat PTSD such as sertraline and paroxetine are effective for the most part in treating these secondary symptoms and do not address the primary intrusion symptoms (7, 8). The results of recent clinical trials with medications such as prazosin and propranolol targeting the primary symptoms in PTSD have been mixed (9–11). Linking novel neurochemical targets with PTSD symptom clusters may allow for the identification of new medications to treat the primary symptoms of PTSD.

Nociceptin (N/OFQ), which binds to the nociceptive opioid peptide receptor (NOP) is an anti-stress/resilience-regulating neuropeptide (12). Recent PET studies with [^{11}C] (S)-3-(2'-fluoro-6',7'-dihydrospiro[piperidine-4,4'-thieno[3,2-c]pyran]-1-yl)-2-(2-fluorobenzyl)-N-methylpropanamide (NOP-1A) allow for the investigation of NOP (13–17). N/OFQ stimulation of NOP receptors inhibit calcium and activates potassium ion channels (18). This allows NOP receptors to regulate the in vivo release of multiple neurotransmitters, including glutamate, gamma-amino butyric acid, dopamine, serotonin and acetylcholine, (19). This mechanism may be of value in targeting the neurochemical abnormalities in PTSD, which involve excitatory, inhibitory and monoamine transmission (20). Studies in control animals show a *reduction* in the number of amygdala NOP receptors during fear conditioning and

expression (21). However, in animals with dysregulated fear either an *upregulation or no change* in NOP receptors is observed in regions such as the amygdala, hippocampus and midbrain (21, 22). These findings have been interpreted variously as representing either an increase or decrease in N/OFQ signaling in PTSD (21, 22). Intriguingly, these contradictory interpretations are supported by studies showing a NOP antagonist and NOP agonist are both effective in alleviating fear, anxiety and pain in rodent models of PTSD (21, 22). In summary, the preclinical literature is mixed with respect to the status of N/OFQ and NOP in animal models of PTSD. In a first step to examine NOP receptors in subjects with a history of trauma, we used PET to measure the in vivo binding of $[^{11}C]$NOP-1A in college women exposed to sexual violence. Consistent with the NIMH Research Domain Criteria (RDoC) initiative, we scanned subjects irrespective of whether they met the full DSM-5 diagnostic criteria for PTSD. We focused on sexual violence in adolescence and early adulthood to minimize the impact of childhood trauma on NOP.

MATERIALS AND METHODS

Human Subjects

The University of Pittsburgh IRB approved the study. All subjects provided written informed consent. Subjects were recruited via advertisements in college newspapers, online ads, a university research registry and college campus sexual assault survivor support groups.

Study criteria for women who have experienced sexual violence were: (1) females 18–25 years old who (2) experienced sexual violence as a teenager or young adult (14 to 25 years of age) excluding subjects with acute trauma (< past 30 days); (3) no history of childhood physical or sexual abuse; (4) no history of DSM-5 psychiatric or addictive disorders other than PTSD; (5) no current use of any drugs of abuse; (6) not currently on psychotropic medication; (7) no medical or neurological illnesses; (8) not currently pregnant; (9) no significant prior exposure to radiation; (10) no contraindications for MRI.

Study criteria for controls were: (1) females 18–25 years old; (2) no history of exposure to actual or threatened sexual violence; (3) no history of childhood physical or sexual abuse; (4) no history of DSM-5 disorders; and criteria 5 through 10 as listed above.

Clinical assessments performed included the: (i) Structured Clinical Interview for DSM-5 to exclude any psychiatric and addictive disorders other than PTSD (23), (ii) Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) to assess PTSD symptom severity. This scale measured the severity of PTSD symptoms as experienced by the subject in the past month prior to PET (past month), and in the worst month after sexual violence (worst month). CAPS-5 scores for the worst month were obtained via the subjects' recall of the symptoms suffered months or years ago. CAPS-5 total symptom severity scores were calculated by summing severity scores of the individual symptoms in all four clusters: intrusion symptoms (cluster B), avoidance symptoms (cluster C), cognitive and mood symptoms (cluster D), and arousal and reactivity symptoms (cluster E) (24), (iii) Life Stressor Checklist-Revised (LSC-R) to exclude any childhood physical or sexual abuse (25), (iv) Hamilton Rating Scale for Anxiety (HAM-A) and Depression (HAM-D) (26, 27), and (v) Alcohol Use Disorders Identification Test (AUDIT) to quantify alcohol abuse (28).

Image acquisition and analysis

Prior to PET imaging, a structural MRI scan was obtained using a Siemens 3T Trio scanner for brain region of interest determination. The synthesis of [^{11}C]NOP-1A was carried out as previously described (13). PET imaging sessions were conducted with the Siemens Biograph64 mCT scanner. The injected dose and mass of [^{11}C]NOP-1A were restricted to 12 mCi and 4.2 µg (29). Following a low-dose CT scan of the brain acquired for attenuation correction, subjects received an intravenous bolus injection of [^{11}C]NOP-1A and emission data were collected for 70 minutes (17). Metabolite-corrected arterial input function measurements were performed and analyzed as described in (13, 16, 17, 29, 30). Free fraction (f_P) was determined in plasma and a saline buffer (to determine filter retention of the free tracer) using ultrafiltration (31, 32).

PET data were reconstructed using filtered back projection. The image analysis software PMOD was used to conduct frame-to-frame motion correction and MR-PET coregistration. Regions of interest were generated for each subject using the built-in brain parcellation work-flow within PMOD's Neuro Tool (PNEURO). Region generation was based on the AAL-VOIs atlas (33, 34). Regions of interest (ROIs) included the amygdala, hippocampus, insula, midbrain, cerebellum, striatum (ventral striatum, caudate and putamen), and prefrontal cortex (specifically the dorsolateral, orbital, medial, and anterior cingulate cortex) subdivisions (30). All regions generated were visually inspected and adjusted as deemed necessary by an image analyst trained in manual region drawing. Regional volumes and time activity curves were also generated in PMOD. Derivation of [^{11}C]NOP-1A volume of distribution expressed relative to total plasma concentration (V_T) in the regions of interest were performed using a two-tissue compartment kinetic analysis using the arterial input function implemented in MATLAB (17, 29, 35). V_T, which includes both the receptor-bound specific and non-specific binding, was used as the outcome measure (16).

Statistical analysis

All statistical analyses were conducted using IBM SPSS v.25. Comparisons between the sexual violence and healthy control groups on the demographic variables and baseline scan parameters (such as injected dose, mass, plasma clearance) were performed with unpaired t-tests. The primary analyses conducted were correlational in nature, because not all subjects who had experienced sexual violence met the DSM-5 diagnostic criteria for PTSD. Normality of the data used were confirmed using Shapiro-Wilk tests prior to correlations. The relationship between regional [^{11}C]NOP-1A V_T and the severity of CAPS-5 PTSD symptoms (past and worst months) were examined with Pearson product moment correlation coefficient. The same test was also used to explore relationships between regional [^{11}C]NOP-1A V_T and other clinical rating scales, such as HAM-A, HAM-D and AUDIT. DSM-5 PTSD diagnosis-based group differences in [^{11}C]NOP-1A V_T were also explored with a linear mixed model (LMM) analysis performed with ROI as a repeated measure and diagnosis as the fixed factor. Regions and diagnosis by regions interaction were included in the model as explanatory variables. A two-tailed probability value of $p < 0.05$ was selected as the significance level for all analyses.

RESULTS

Eighteen women who had experienced sexual violence were matched with 18 controls on age, ethnicity, and nicotine status. Nine of 18 subjects in the sexual violence group met CAPS-5 PTSD diagnostic criteria in the past month (PTSD-PM); an additional 5 subjects met the CAPS-5 PTSD diagnostic criteria in their worst (PTSD-WM) but not past month; and 4 subjects did not meet the CAPS-5 PTSD diagnostic criteria in their worst or past month (RESILIENT). Table 1 lists demographic variables and clinical characteristics of the study sample. Sexual violence subjects had significantly higher anxiety, depression and life stressors (other LSC-R traumatic events reported by the sexual violence subjects are included in the supplement, Table S1) compared to controls. No significant group differences were observed in the AUDIT scores.

[^{11}C]NOP-1A PET scan data

Tables 2 and 3 shows [^{11}C]NOP-1A scan parameters and regional V_T in women who have experienced sexual violence and controls. No significant between-group differences were noted in any of the scan parameters (see Table 2), regional volumes (data not shown) and V_T (LMM effect of group, $F (1, 34) = 0.15$, $p = 0.70$; effect of region, $F (11, 374) = 537.07$, $p < 0.001$, region * diagnosis interaction, $F (11, 374) = 0.48$, $p = 0.92$, see data in Table 3).

Relationship between V_T and CAPS-5 symptoms:

In the past month prior to PET—There were significant positive correlations between V_T and past month CAPS-5 total symptom severity scores (bivariate). This relationship was significant in the midbrain and cerebellum (Figure 1), but not other ROIs (data not shown). These relationships remained significant with the use of non-parametric Spearman's rank-order correlation tests (see supplement). These relationships were also significant when examined with partial correlations that controlled for the effect of HAM-D scores (midbrain, $r = 0.77$, $p = 0.0003$; and cerebellum, $r = 0.79$, $p = 0.00015$). Although there was no relationship between HAM-D scores and V_T (see supplement) this was done because the spread of the HAM-D scores in the sexual violence group was relatively large (5 to 17; with six out of eighteen sexual violence subjects with HAM-D scores   10). These partial, but not bivariate correlations survived the Bonferroni correction (12 regions × 2 sets of CAPS-5 scores, past-month and worst-month; $p = 0.05/24$ 0.002).

Removal of the four RESILIENT subjects who did not meet diagnostic criteria for PTSD in their worst or past month had no effect on the statistical significance of these correlations. Removal of the two subjects who used nicotine did not alter the correlation coefficient (r), but it changed the p-values for the relationships between *past month* CAPS-5 total severity scores and V_T to trend-level (see supplement, Table S3).

Midbrain and cerebellum V_T were positively correlated with past month clusters B (see Figure 2) and C (midbrain: $r = 0.53$, $p = 0.02$, and cerebellum: $r = 0.54$, $p = 0.02$), but not D (midbrain: $r = 0.28$, $p = 0.25$, and cerebellum: $r = 0.28$, $p = 0.26$) and E severity scores (midbrain: $r = 0.40$, $p = 0.10$, and cerebellum: $r = 0.37$, $p = 0.13$).

In the worst month after sexual violence—There were no significant correlations between V_T and worst month CAPS-5 total symptom (or cluster) severity scores.

Relationship between V_T and other clinical parameters

No significant relationships were noted between regional V_T and HAM-A, HAM-D and AUDIT scores in the control or sexual violence groups. There was also no relationship between V_T and the time that had elapsed since sexual violence (i.e., trauma window, see supplemental data).

DSM-5 PTSD diagnosis and [^{11}C]NOP-1A V_T

No differences in [^{11}C]NOP-1A V_T were observed in subjects with a diagnosis of PTSD-PM (n = 9 out of 18 in sexual violence group) compared to controls (LMM, effect of diagnosis, F (1, 25) = 0.27, p = 0.61; effect of region, F (11, 275) = 315.29, p < 0.001, region * diagnosis interaction, F (11, 275) = 0.42, p = 0.95).

No differences in [^{11}C]NOP-1A V_T were observed in subjects with a diagnosis of PTSD-WM (n = 14 out of 18 in sexual violence group) compared to controls (LMM, effect of diagnosis, F (1, 30) = 0.08, p = 0.78; effect of region, F (11, 330) = 434.95, p < 0.001, region * diagnosis interaction, F (11, 330) = 0.55, p = 0.87).

DISCUSSION

In this [^{11}C]NOP-1A PET imaging study, we scanned college women who had experienced sexual violence irrespective of whether they met the DSM-5 diagnostic criteria for PTSD in the past or worst month. The results of this study show that increased midbrain and cerebellum V_T is related to greater PTSD symptoms. This relationship with V_T was significant for PTSD symptoms experienced in the recent past, but not worst month since sexual violence. This suggests that increased NOP receptors in women who have experienced sexual violence is an adaptive response to *ongoing* as opposed to *historical* PTSD symptoms. However, these PET data do not exclude the possibility that women with increased NOP-R (e.g., genetically determined) may be at greater risk to develop long-lasting PTSD symptoms. This interpretation is supported by the inclusion of women who were resilient and recovered from PTSD in this study. The intrusion, re-experiencing, and avoidance symptoms presently considered primary features of PTSD were strongly associated with V_T (1). No such associations were noted with the secondary mood, cognition, arousal and reactivity symptoms of PTSD. DSM-5 based stratification of the sexual violence subjects into groups (PTSD-PM, PTSD-WM and RESILIENT) and contrasting them with controls revealed no differences in V_T.

The positive association observed between PTSD symptom severity and [^{11}C]NOP-1A V_T in the midbrain and cerebellum suggest a role for N/OFQ and NOP in recovery following trauma. An increase in NOP mRNA in the limbic-related brain regions has been reported following restraint stress (37), social defeat stress (38), social crowding (39) and the single-prolonged stress exposure paradigm (22). Increases in N/OFQ signaling could be accomplished either via increased N/OFQ release or an upregulation of NOP receptors. Studies have reported mixed results and lack consensus with respect to whether N/OFQ

levels increase in the brain following stress (37, 40–42). This has led to the postulation that an upregulation of NOP receptors in response to stress is an adaptive physiological response to enhance N/OFQ signaling in the brain (37). Further supportive of this is a study in which an upregulation of NOP, but not N/OFQ mRNA, was observed in the bed nucleus of the stria terminalis following an acute increase in the stress-mediating neuropeptide corticotrophin releasing factor (43). Increased NOP in more severe PTSD might also reflect lower levels of the endogenous neurotransmitter N/OFQ. Such lines of reasoning would support a therapeutic role for NOP agonists in promoting both resilience and recovery in PTSD (21, 44). Intriguingly, a retrospective study found that the weak NOP agonist buprenorphine was more effective than opioid agonists, which have no NOP affinity, in improving PTSD symptoms in veterans with chronic pain and opioid use disorders (45). However, animal studies also support a role for NOP antagonists in treating PTSD (22, 46). The correlational results from this PET study implicate NOP, but do not necessarily inform the field as to whether a NOP agonist or antagonist will be successful in treating PTSD. Future clinical trials with NOP compounds are necessary to clarify their therapeutic role, if any, in PTSD.

The correlational findings in this study involved the midbrain (substantia nigra, raphe nucleus, ventral tegmental area and red nucleus) and cerebellum. The involvement of the midbrain and cerebellum in a cerebellar-limbic-thalamo-cortical network that functions as an innate alarm system in response to a threat is consistent with emerging imaging literature in PTSD (47). In addition to the established role of the midbrain in regulating startle, hypervigilance and escape, these studies suggest that the midbrain and cerebellum process subconscious fear- and trauma-related cues in PTSD (48, 49). The periaqueductal gray matter (PAG), a part of the midbrain, elicits adaptive behaviors in response to a threat (50). The cerebellum, which receives teaching signals via climbing fibers from the olivary nucleus, is involved in the learning of complex cognitive processes including emotions (50). Studies also suggest that the cerebellum plays a role similar to the amygdala in the consolidation of fear-conditioned memories and fear expression (51). Basic studies have also demonstrated direct and indirect (via inferior olivary nucleus) connections between the PAG and the cerebellum (50). The PAG gates sensory information to the cerebellum via these connections. It also influences the motor output from cerebellar nuclei, which when combined with its own control over spinal motor reflex pathways allows an animal to freeze, get ready and escape danger (50, 52). In summary, basic data suggest that the clinical correlations involving the midbrain and cerebellum are relevant. However, replication of these correlational findings in a larger sample of individuals with more diverse traumatic experiences is necessary to confirm them.

Numerous investigations have implicated N/OFQ and NOP in animal models of learning and memory (reviewed in 44). N/OFQ impairs fear acquisition and memory consolidation in a range of behavioral paradigms, including the contextual/auditory fear conditioning, object recognition, passive avoidance learning and water maze tests. It also disrupts the retrieval and reconsolidation of previously consolidated traumatic memories (53). N/OFQ inhibits K+ stimulated glutamate release by ~38% in rodent cerebellum and midbrain slices; the exact same regions in which we observed clinical correlations between NOP and intrusive symptoms (54). The mechanism by which N/OFQ disrupts trauma-related memory consolidation involves its ability to inhibit glutamate release and interrupt NMDA-mediated

long-term potentiation (44, 55). N/OFQ also inhibits the release of monoamine neurotransmitters such as dopamine, acetylcholine, serotonin, and norepinephrine; all of which are involved in cue-induced and context dependent learning, and likely relevant to its ability to disrupt the formation of trauma-related memories (44). Increased NOP receptors in women with intrusive trauma-related memories after sexual violence might be reflective of a continued effort by the brain to enhance N/OFQ signaling to reduce glutamate and monoamine transmission. Imaging studies examining the interactions between NOP – glutamate, NOP – dopamine, and linking them with intrusive traumatic memories and fear expression in PTSD are necessary to clarify this mechanism. The lack of a relationship between [^{11}C]NOP-1A V_T and anxiety/depressive symptoms is inconsistent with basic reports (56). The relatively low level of anxiety and depressive symptoms (scores on HAM-A = 7 ± 3; and HAM-D = 8 ± 3) in subjects who had experienced sexual violence may have contributed to the inability to detect a relationship with V_T. However, the failure to observe this relationship is consistent with what we have recently reported with [^{11}C]NOP-1A PET in individuals with addictive disorders (30). There were no DSM-5 PTSD diagnosis-based group differences in V_T compared to healthy controls (see Figure 3). It is tempting to ascribe this to an insufficient number of subjects with a diagnosis of PTSD in this study. However, the effect size to detect group differences between individuals with PTSD in the past month vs. controls is a modest 0.46 (when derived using data from the midbrain, the region in which we found the strongest clinical correlation- see Figure 3). Power calculations using this effect size suggest a need to enroll n = 124 subjects/group to detect between-group differences when using a two tailed unpaired t-test with a p-value < 0.05. Future [^{11}C]NOP-1A studies in psychiatric and addictive disorders should focus not only demonstrating group differences, but also examine the relationship between NOP V_T and clinical symptoms.

A limitation of the study is that it is unclear whether factors such as the phase of menstrual cycle, hormonal contraceptive use, and nicotine use influenced the correlational findings observed in this study. No studies have examined the effects of menstrual cycle phases on NOP receptor expression in brain regions such as the midbrain and cerebellum. However, recent investigations in the spinal cord trigeminal neurons and hypothalamus (a unique brain region, which regulates the synthesis of sex steroids) suggest that the progesterone to estrogen ratio, which fluctuates during the menstrual cycle influences NOP receptor expression and binding. These studies have reported increases in NOP in the hypothalamic nuclei following both estrogen and estrogen + progesterone treatment; and decreases in NOP in the trigeminal neurons during the proestrous (high estrogen/low progesterone) compared to diestrous (low estrogen/high progesterone) phase of the rodent menstrual cycle (57, 58). It is unclear as to whether, and how menstrual cycle phase may have influenced [^{11}C]NOP-1A V_T measurements in the midbrain and cerebellum in this imaging study. A retrospective evaluation of the phase of menstrual cycle based on the subjects' self-reported last menstrual period before the scan shows that the majority of women with a history of sexual violence were scanned either in the luteal phase or when on a hormone-based contraceptive (n = 16/18, see Table 1). This is reassuring as it suggests relative stability in estrogen and progesterone levels at the time of the PET scan in women who experienced sexual violence, despite higher levels in luteal phase (n = 5), and lower levels on hormonal contraceptives (n

= 11) (59, 60). Furthermore, no significant differences in V_T in the midbrain and cerebellum in women scanned in follicular phase, luteal phase, or hormone-based contraceptives also suggest a limited effect for sex-hormone ratio on NOP binding (Supplement, Table S2). Nevertheless, it seems prudent for future [^{11}C]NOP-1A PET studies in women to measure serum estrogen and progesterone levels at time of the PET scan to exclude the effects of sex hormones on V_T. With respect to another confound, the use of nicotine, only 2/18 subjects who experienced sexual violence were smokers. Excluding these individuals from the analysis did not change correlation coefficient (r), but it changed the p-value to a trend (from significant) for the relationship between V_T and CAPS-5 total symptom severity (this was not the case for the relationship between CAPS-5 intrusion symptoms and V_T). This is likely attributable to a loss of power as opposed to the influence of smoking status on the relationship. This interpretation is supported by our legacy [^{11}C]NOP-1A data in healthy controls in which we find no significant differences in V_T based on smoking status (Supplement, Table S4). Based on this we conclude that the impact of smoking is minimal on the findings reported in this study. Other limitations of the study are the exclusion of a clinically representative sample of PTSD with more diverse trauma and severe symptoms because of the concerns of comorbidity and psychiatric medications. The inability to exclude individual differences in [^{11}C]NOP-1A non-specific binding (V_{ND}) as a contributor to V_T is also a concern for which there was no technical solution. This concern is somewhat alleviated by prior blocking studies in humans that have demonstrated that 50–75% of [^{11}C]NOP-1A V_T represents specific binding to NOP (61). In summary, we showed a relationship between [^{11}C]NOP-1A V_T and the severity of post-traumatic stress symptoms in college women who had experienced sexual violence during adolescence/young adulthood. These correlational data were also supportive of a role for NOP in mediating trauma-related intrusion and avoidance symptoms. The approach used in this study highlights the continued need to investigate the pathophysiology of psychiatric disorders using a DSM-5 agnostic approach as recommended in the NIMH RDoC initiative.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS.

REFERENCES

1. Ross DA, Arbuckle MR, Travis MJ, Dwyer JB, van Schalkwyk GI, Ressler KJ (2017): An Integrated Neuroscience Perspective on Formulation and Treatment Planning for Posttraumatic Stress Disorder: An Educational Review. JAMA psychiatry. 74:407–415. [PubMed: 28273291]

2. Walsh K, Danielson CK, McCauley JL, Saunders BE, Kilpatrick DG, Resnick HS (2012): National prevalence of posttraumatic stress disorder among sexually revictimized adolescent, college, and adult household-residing women. Arch Gen Psychiatry. 69:935–942. [PubMed: 22566561]

3. Fedina L, Holmes JL, Backes BL (2016): Campus Sexual Assault: A Systematic Review of Prevalence Research From 2000 to 2015. Trauma Violence Abuse.

4. Resnick HS, Kilpatrick DG, Dansky BS, Saunders BE, Best CL (1993): Prevalence of civilian trauma and posttraumatic stress disorder in a representative national sample of women. J Consult Clin Psychol. 61:984–991. [PubMed: 8113499]

5. Creamer M, Burgess P, McFarlane AC (2001): Post-traumatic stress disorder: findings from the Australian National Survey of Mental Health and Well-being. Psychol Med. 31:1237–1247. [PubMed: 11681550]

6. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005): Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 62:593–602. [PubMed: 15939837]

7. Davidson JR, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM (2001): Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry. 58:485–492. [PubMed: 11343529]

8. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, et al. (2000): Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA. 283:1837–1844. [PubMed: 10770145]

9. Argolo FC, Cavalcanti-Ribeiro P, Netto LR, Quarantini LC (2015): Prevention of posttraumatic stress disorder with propranolol: A meta-analytic review. J Psychosom Res. 79:89–93. [PubMed: 25972056]

10. Brunet A, Saumier D, Liu A, Streiner DL, Tremblay J, Pitman RK (2018): Reduction of PTSD Symptoms With Pre-Reactivation Propranolol Therapy: A Randomized Controlled Trial. Am J Psychiatry. 175:427–433. [PubMed: 29325446]

11. Raskind MA, Peskind ER, Chow B, Harris C, Davis-Karim A, Holmes HA, et al. (2018): Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans. N Engl J Med. 378:507–517. [PubMed: 29414272]

12. Koob GF (2008): A role for brain stress systems in addiction. Neuron. 59:11–34. [PubMed: 18614026]

13. Pike VW, Rash KS, Chen Z, Pedregal C, Statnick MA, Kimura Y, et al. (2011): Synthesis and evaluation of radioligands for imaging brain nociceptin/orphanin FQ peptide (NOP) receptors with positron emission tomography. J Med Chem. 54:2687–2700. [PubMed: 21438532]

14. Berthele A, Platzer S, Dworzak D, Schadrack J, Mahal B, Buttner A, et al. (2003): [3H]-nociceptin ligand-binding and nociceptin opioid receptor mrna expression in the human brain. Neuroscience. 121:629–640. [PubMed: 14568023]

15. Bridge KE, Wainwright A, Reilly K, Oliver KR (2003): Autoradiographic localization of (125)i[Tyr(14)] nociceptin/orphanin FQ binding sites in macaque primate CNS. Neuroscience. 118:513–523. [PubMed: 12699786]

16. Kimura Y, Fujita M, Hong J, Lohith TG, Gladding RL, Zoghbi SS, et al. (2011): Brain and whole-body imaging in rhesus monkeys of 11C-NOP-1A, a promising PET radioligand for nociceptin/orphanin FQ peptide receptors. J Nucl Med. 52:1638–1645. [PubMed: 21880575]

17. Lohith TG, Zoghbi SS, Morse CL, Araneta MF, Barth VN, Goebl NA, et al. (2012): Brain and whole-body imaging of nociceptin/orphanin FQ peptide receptor in humans using the PET ligand 11C-NOP-1A. J Nucl Med. 53:385–392. [PubMed: 22312136]

18. Toll L, Bruchas MR, Calo G, Cox BM, Zaveri NT (2016): Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems. Pharmacol Rev. 68:419–457. [PubMed: 26956246]

19. Schlicker E, Morari M (2000): Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system. Peptides. 21:1023–1029. [PubMed: 10998536]

20. Kelmendi B, Adams TG, Yarnell S, Southwick S, Abdallah CG, Krystal JH (2016): PTSD: from neurobiology to pharmacological treatments. Eur J Psychotraumatol. 7:31858. [PubMed: 27837583]

21. Andero R, Brothers SP, Jovanovic T, Chen YT, Salah-Uddin H, Cameron M, et al. (2013): Amygdala-dependent fear is regulated by Oprl1 in mice and humans with PTSD. Science translational medicine. 5:188ra173.

22. Zhang Y, Simpson-Durand CD, Standifer KM (2015): Nociceptin/orphanin FQ peptide receptor antagonist JTC-801 reverses pain and anxiety symptoms in a rat model of post-traumatic stress disorder. Br J Pharmacol. 172:571–582. [PubMed: 24666365]

23. First M, Williams JBW, Karg RS, Spitzer RL (2015): Structured Clinical Interview for DSM-5—Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV). Arlington, VA: American Psychiatric Association 2015.

24. Weathers FW, Bovin MJ, Lee DJ, Sloan DM, Schnurr PP, Kaloupek DG, et al. (2018): The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans. Psychol Assess. 30:383–395. [PubMed: 28493729]

25. Wolfe J, Kimerling R, Brown P, Chrestman K, Levin K (1997): Life Stressor Checklist-Revised (LSC-R). www.ptsd.va.gov/professional/assessment/te-measures/lsc-r.asp.

26. Hamilton M (1959): The assessment of anxiety scales by rating. Br J Med Psychol. 32.

27. Hamilton M (1960): A rating scale for depression. J Neurol Neurosurg Psych. 23:56–62.

28. Bohn MJ, Babor TF, Kranzler HR (1995): The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol. 56:423–432. [PubMed: 7674678]

29. Lohith TG, Zoghbi SS, Morse CL, Araneta MD, Barth VN, Goebl NA, et al. (2014): Retest imaging of [11C]NOP-1A binding to nociceptin/orphanin FQ peptide (NOP) receptors in the brain of healthy humans. Neuroimage. 87:89–95. [PubMed: 24225488]

30. Narendran R, Ciccocioppo R, Lopresti B, Paris J, Himes ML, Mason NS (2017): Nociceptin Receptors in Alcohol Use Disorders: A Positron Emission Tomography Study Using [11C]NOP-1A. Biol Psychiatry. In press.

31. Gandelman MS, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Innis RB (1994): Evaluation of ultrafiltration for the free fraction determination of single photon emission computerized tomography (SPECT) radiotracers: b-CIT, IBF and iomazenil. J Pharmaceutical Sci. 83:1014–1019.

32. Narendran R, Frankle WG, Mason NS, Rabiner EA, Gunn RN, Searle GE, et al. (2009): Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: a comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB 457 and [11C]fallypride. Synapse. 63:447–461. [PubMed: 19217025]

33. Tzourio-Mazoyer N L B, Papathanassiou D, Crivello F, Étard O, Delcroix N, Mazoyer B, and Joliot M (2002): Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain. NeuroImage. 15:273–289. [PubMed: 11771995]

34. Collins DZ, AP; Kollokian V; Sled JG; Kabani NJ; Holmes CJ; Evans AC (1998): Design and construction of a realistic digital brain phantom. IEEE Transactions on Medical Imaging. 17:463–468. [PubMed: 9735909]

35. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. (2007): Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 27:1533–1539. [PubMed: 17519979]

36. Post A, Smart TS, Jackson K, Mann J, Mohs R, Rorick-Kehn L, et al. (2016): Proof-of-Concept Study to Assess the Nociceptin Receptor Antagonist LY2940094 as a New Treatment for Alcohol Dependence. Alcohol Clin Exp Res. 40:1935–1944. [PubMed: 27435979]

37. Ciccocioppo R, de Guglielmo G, Hansson AC, Ubaldi M, Kallupi M, Cruz MT, et al. (2014): Restraint stress alters nociceptin/orphanin FQ and CRF systems in the rat central amygdala: significance for anxiety-like behaviors. J Neurosci. 34:363–372. [PubMed: 24403138]

38. Green MK, Devine DP (2009): Nociceptin/orphanin FQ and NOP receptor gene regulation after acute or repeated social defeat stress. Neuropeptides. 43:507–514. [PubMed: 19720395]

39. Reiss D, Wolter-Sutter A, Krezel W, Ouagazzal AM (2007): Effects of social crowding on emotionality and expression of hippocampal nociceptin/orphanin FQ system transcripts in mice. Behav Brain Res. 184:167–173. [PubMed: 17697718]

40. Der-Avakian A, D'Souza MS, Potter DN, Chartoff EH, Carlezon WA Jr., Pizzagalli DA, et al. (2017): Social defeat disrupts reward learning and potentiates striatal nociceptin/orphanin FQ mRNA in rats. Psychopharmacology (Berl). 234:1603–1614. [PubMed: 28280884]

41. Nativio P, Pascale E, Maffei A, Scaccianoce S, Passarelli F (2012): Effect of stress on hippocampal nociceptin expression in the rat. Stress. 15:378–384. [PubMed: 22074385]

42. Devine DP, Hoversten MT, Ueda Y, Akil H (2003): Nociceptin/orphanin FQ content is decreased in forebrain neurones during acute stress. J Neuroendocrinol. 15:69–74. [PubMed: 12535171]

43. Rodi D, Zucchini S, Simonato M, Cifani C, Massi M, Polidori C (2008): Functional antagonism between nociceptin/orphanin FQ (N/OFQ) and corticotropin-releasing factor (CRF) in the rat brain: evidence for involvement of the bed nucleus of the stria terminalis. Psychopharmacology (Berl). 196:523–531. [PubMed: 17989958]

44. Andero R (2015): Nociceptin and the nociceptin receptor in learning and memory. Prog Neuropsychopharmacol Biol Psychiatry. 62:45–50. [PubMed: 25724763]

45. Seale JP, Dittmer T, Sigman EJ, Clemons H, Johnson JA (2014): Combined abuse of clonidine and amitriptyline in a patient on buprenorphine maintenance treatment. J Addict Med. 8:476–478. [PubMed: 25314340]

46. Zhang Y, Gandhi PR, Standifer KM (2012): Increased nociceptive sensitivity and nociceptin/ orphanin FQ levels in a rat model of PTSD. Mol Pain. 8:76. [PubMed: 23082795]

47. Lanius RA, Rabellino D, Boyd JE, Harricharan S, Frewen PA, McKinnon MC (2017): The innate alarm system in PTSD: conscious and subconscious processing of threat. Curr Opin Psychol. 14:109–115. [PubMed: 28813307]

48. Rabellino D, Densmore M, Frewen PA, Theberge J, Lanius RA (2016): The innate alarm circuit in post-traumatic stress disorder: Conscious and subconscious processing of fear- and trauma-related cues. Psychiatry Res Neuroimaging. 248:142–150. [PubMed: 26749205]

49. Steuwe C, Daniels JK, Frewen PA, Densmore M, Pannasch S, Beblo T, et al. (2014): Effect of direct eye contact in PTSD related to interpersonal trauma: an fMRI study of activation of an innate alarm system. Social cognitive and affective neuroscience. 9:88–97. [PubMed: 22977200]

50. Watson TC, Koutsikou S, Cerminara NL, Flavell CR, Crook JJ, Lumb BM, et al. (2013): The olivo-cerebellar system and its relationship to survival circuits. Front Neural Circuits. 7:72. [PubMed: 23630468]

51. Strata P, Scelfo B, Sacchetti B (2011): Involvement of cerebellum in emotional behavior. Physiol Res. 60 Suppl 1:S39–48. [PubMed: 21777033]

52. Koutsikou S, Watson TC, Crook JJ, Leith JL, Lawrenson CL, Apps R, et al. (2015): The Periaqueductal Gray Orchestrates Sensory and Motor Circuits at Multiple Levels of the Neuraxis. J Neurosci. 35:14132–14147. [PubMed: 26490855]

53. Rekik K, Faria Da Silva R, Colom M, Pacifico S, Zaveri NT, Calo G, et al. (2017): Activation of nociceptin/orphanin FQ receptors inhibits contextual fear memory reconsolidation. Neuropharmacology. 125:39–49. [PubMed: 28705439]

54. Nicol B, Lambert DG, Rowbotham DJ, Okuda-Ashitaka E, Ito S, Smart D, et al. (1998): Nocistatin reverses nociceptin inhibition of glutamate release from rat brain slices. Eur J Pharmacol. 356:R1–3. [PubMed: 9774260]

55. Goeldner C, Reiss D, Wichmann J, Meziane H, Kieffer BL, Ouagazzal AM (2008): Nociceptin receptor impairs recognition memory via interaction with NMDA receptor-dependent mitogen-activated protein kinase/extracellular signal-regulated kinase signaling in the hippocampus. J Neurosci. 28:2190–2198. [PubMed: 18305252]

56. Mallimo EM, Kusnecov AW (2013): The role of orphanin FQ/nociceptin in neuroplasticity: relationship to stress, anxiety and neuroinflammation. Front Cell Neurosci. 7:173. [PubMed: 24155687]

57. Sinchak K, Dalhousay L, Sanathara N (2015): Orphanin FQ-ORL-1 regulation of reproduction and reproductive behavior in the female. Vitamins and hormones. 97:187–221. [PubMed: 25677773]

58. Flores CA, Shughrue P, Petersen SL, Mokha SS (2003): Sex-related differences in the distribution of opioid receptor-like 1 receptor mRNA and colocalization with estrogen receptor mRNA in neurons of the spinal trigeminal nucleus caudalis in the rat. Neuroscience. 118:769–778. [PubMed: 12710984]

59. Reed BG, Carr BR (2000): The Normal Menstrual Cycle and the Control of Ovulation In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, et al., editors. Endotext. South Dartmouth (MA).

60. Gaspard UJ, Romus MA, Gillain D, Duvivier J, Demey-Ponsart E, Franchimont P (1983): Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel. Contraception. 27:577–590. [PubMed: 6225622]

61. Raddad E, Chappell A, Meyer J, Wilson A, Ruegg CE, Tauscher J, et al. (2016): Occupancy of Nociceptin/Orphanin FQ Peptide Receptors by the Antagonist LY2940094 in Rats and Healthy Human Subjects. Drug Metab Dispos. 44:1536–1542. [PubMed: 27353045]

Figure 1.

shows the relationship between $[^{11}C]NOP\text{-}1A$ V_T and CAPS-5 total symptoms score. Increased binding to NOP receptors in the midbrain (1a) and cerebellum (1b) in women who have experienced sexual violence is associated with more severe PTSD symptoms.

Figure 2.
shows the relationship between midbrain (2a) and cerebellum (2b) V_T and CAPS-5 intrusion (cluster B) symptoms score. Increased binding to NOP receptors in women who have experienced sexual violence is associated with more severe PTSD intrusion symptoms.

**Figure 3.**
shows the lack of DSM-5 based diagnostic group differences in [11C]NOP-1A midbrain binding between PTSD in past month (PM) vs. PTSD in worst month (WM) vs. no PTSD in past and/or worst month (RESILIENT) vs. healthy controls with no prior history of sexual violence.

Table 1.

Demographic and clinical characteristics of the sample

	Experienced sexual violence Mean ± SD	Healthy Controls Mean ± SD
N	18	18
Age	22 ± 2	22 ± 2
Race		
African American	2	1
Asian	2	3
Hispanic	0	1
Caucasian	13	12
More than one race	1	1
Nicotine use	2	2
Sex hormone status		
Follicular phase	0	4
Luteal phase	5	1
Hormone based contraception	11	10
Unable to determine	2	3
Exposure to sexual violence (single/multiple)	10/8	-
Trauma window (i.e., time in months between initial trauma and PET)	36 ± 22	
Clinician-Administered PTSD Scale for DSM V		
Worst month		
PTSD Diagnosis criteria met in N	14	-
PTSD Total symptoms score (0 to 80)	48 ± 22	-
Past month		
PTSD Diagnosis criteria met in N	9	-
PTSD Total symptoms score (0 to 80)	22 ± 15	-
Subscale scores:		
Cluster B Intrusion symptoms score (0 to 20)	5 ± 4	-
Cluster C Avoidance symptoms score (0 to 8)	3 ± 2	-
Cluster D Cognitions and mood symptoms score (0 to 28)	8 ± 6	-
Cluster E Arousal and reactivity symptoms score (0 to 24)	6 ± 5	-

	Experienced sexual violence Mean ± SD	Healthy Controls Mean ± SD
Dissociative symptoms score (0 to 8)	1 ± 1	-
[†]Life stressor checklist (0 to 30)	6 ± 3	2 ± 1[*]
Hamilton anxiety rating scale (0 to 56)	7 ± 4	2 ± 2[*]
[†]Hamilton depression rating scale (0 to 68)	8 ± 3	3 ± 2[*]
[†]Alcohol use disorders identification test (0 to 40)	6 ± 6	4 ± 2

[*]
p 0.05, unpaired t-tests; SD, standard deviation

[†]
data was available for only n=12 out of 18 healthy controls

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2.

[^{11}C]NOP-1A PET scan parameters

Scan Parameter	Experienced sexual violence (n = 18) Mean ± SD	Healthy Controls (n = 18) Mean ± SD
Injected dose (mCi)	12.4 ± 0.7	12.3 ± 0.8
Specific Activity (Ci/mmoles)	2118 ± 1022	2396 ± 785
Injected mass (μg)	2.9 ± 1.0	2.4 ± 0.8
Plasma free fraction (f_P, %)	14.1% ± 2.3%	14.4% ± 2.3%
Saline buffer free fraction (fp, %)	66.5% ± 12.7%	73.7% ± 11.0%
Clearance (L/h)	149.1 ± 33.9	129.0 ± 27.5

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3.

Regional [^{11}C]NOP-1A V_T in women who have experienced sexual violence and controls

Regions of interest	Experienced sexual violence (n = 18) Mean ± SD	Healthy Controls (n = 18) Mean ± SD
Amygdala	13.9 ± 2.2	14.3 ± 1.9
Hippocampus	10.5 ± 1.3	10.6 ± 2.0
Midbrain	8.6 ± 1.2	8.7 ± 1.0
Ventral Striatum	13.6 ± 1.8	13.9 ± 1.7
Caudate	11.2 ± 1.6	11.2 ± 1.4
Putamen	12.6 ± 1.8	12.7 ± 1.5
Dorsolateral Prefrontal Cortex	12.8 ± 1.8	13.0 ± 1.6
Orbital Frontal Cortex	13.2 ± 1.6	13.6 ± 1.7
Medial Prefrontal Cortex	12.7 ± 1.8	12.9 ± 1.6
Anterior Cingulate Cortex	12.9 ± 1.7	13.2 ± 1.8
Insula	14.8 ± 2.0	14.9 ± 1.9
Cerebellum	7.5 ± 1.0	7.6 ± 0.8